Efficacy and safety of alpha-pinene capsule in the management of functional dyspepsia and eradication of helicobacter pylori: a randomized clinical trial
Gastroenterology and Hepatology from Bed to Bench,
Vol. 17 No. 2 (2024),
14 Farvardin 2024
https://doi.org/10.22037/ghfbb.v17i2.2903
Abstract
Aim: Our objective was to assess the efficacy and safety of adding alpha-pinene (a herbal terpenoid) to quadruple therapy compared to a placebo in improving symptoms and Helicobacter pylori (H. pylori) eradication rates in Functional dyspepsia (FD) patients.
Background: FD is a prevalent upper gastrointestinal condition, and no definitive pharmacological treatment is available for its management.
Methods: We conducted a randomized, double-blinded, placebo-controlled trial on FD patients diagnosed with H. pylori infection. We collected baseline demographic data and assessed FD symptoms in the participants. Patients were randomly allocated to receive either standard quadruple therapy with α-pinene capsules (0.25 mg/day) or quadruple therapy with a placebo for two weeks. We employed a validated questionnaire, the Short Form Leeds Dyspepsia Questionnaire (SF-LDQ), to evaluate FD symptoms. The eradication rate of H. pylori was compared between the two groups one month after completing the treatment regimens. Any reported adverse drug reactions (ADRs) were documented throughout the trial.
Results: Over four months, a total of 66 patients completed the trial. Notably, there were no significant differences in baseline SF-LDQ scores between the two groups (p=0.83); however, a significant divergence emerged at the trial's conclusion (p=0.03). The H. pylori eradication rates did not show notable differences between the two treatment arms (p=0.43). Importantly, there were no dropouts from the trial due to ADRs. Among reported ADRs, participants experienced abdominal pain, headache, diarrhea, and a metallic taste, with no significant variance in incidence rates observed between the two groups (p=0.62).
Conclusion: These findings suggest that α-pinene could be an effective and safe agent for reducing FD symptoms.
- Alphapinen
- Helicobacter pylori
- functional dyspepsia
- clinical trial
How to Cite
References
Harer KN, Hasler WL. Functional Dyspepsia: a review of the symptoms, evaluation, and treatment options. Gastroenterol Hepatol (N Y). 2020;16:66-74.f:
Stanghellini V, Chan FKL, Hasler WL et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–1392.
Madisch A, Andresen V, Enck P, Labenz J, Frieling T, Schemann M. The Diagnosis and Treatment of Functional Dyspepsia. Dtsch Arztebl Int. 2018; 30;115:222-232
Salehi B, Upadhyay S, Erdogan Orhan I, Kumar Jugran A, L D Jayaweera S, A Dias D, Sharopov F, Taheri Y, Martins N, Baghalpour N, Cho WC, Sharifi-Rad J. Therapeutic Potential of α- and β-Pinene: A Miracle Gift of Nature. Biomolecules. 2019;14:738.
Pinheiro Mde A, Magalhães RM, Torres DM, Cavalcante RC, Mota FS, Oliveira Coelho EM, Moreira HP, Lima GC, Araújo PC, Cardoso JH, de Souza AN, Diniz LR. Gastroprotective effect of alpha-pinene and its correlation with antiulcerogenic activity of essential oils obtained from Hyptis species. Pharmacogn Mag. 2015 ;11:123-30
Eftekharafzali M, Mehrabani M, Tajadini H, Ahmadi B, Zahedi MJ. Effect of “Pistacia Atlantica” Resin (Baneh) on Functional Dyspepsia: A Double Blind, Randomized Clinical Study. Iran Red Crescent Med J. 2018;20:e63822
Afrasiabian H, Imanieh M, Nejati M, Salehi A. The Effect of Oral Administration of Pistacia Atlantica Kurdica Gum on the Eradication of Helicobacter Pylori in Patients with Dyspepsia: A Randomized Clinical Trial. Global Journal of Health Science 2017;9:256-256
Futagami S, Yamawaki H, Agawa S, Higuchi K, Ikeda G, Noda H, Kirita K, Akimoto T, Wakabayashi M, Sakasegawa N, Kodaka Y, Ueki N, Kawagoe T, Iwakiri K. New classification Rome IV functional dyspepsia and subtypes. Transl Gastroenterol Hepatol. 2018;19:70
. Fraser A, Delaney BC, Ford AC, Qume M, Moayyedi P. The Short-Form Leeds Dyspepsia Questionnaire validation study. Aliment Pharmacol Ther. 2007 15;25:477-86.
Nieuwenburg SAV, Mommersteeg MC, Wolters LMM, van Vuuren AJ, Erler N, Peppelenbosch MP, Fuhler GM, Bruno MJ, Kuipers EJ, Spaander MCW. Accuracy of H. pylori fecal antigen test using fecal immunochemical test (FIT). Gastric Cancer. 2022;25:375-381
Murali M, Suppes SL, Feldman K, Goldman JL. Utilization of the Naranjo scale to evaluate adverse drug reactions at a free-standing children’s hospital. PLoS ONE 2021;16: e0245368
Mukhtar M, Zubair M, Naz R, Tabassum S, Achackzai MA. Functional Dyspepsia: An Unresolved Issue. Intern Med 2015; 5: 192
Gwee KA, Holtmann G, Tack J, Suzuki H, Liu J, Xiao Y, Chen MH, Hou X, Wu DC, Toh C, Lu F, Tang XD. Herbal medicines in functional dyspepsia-Untapped opportunities not without risks. Neurogastroenterol Motil. 2021;33:e1404
Abbasinazari M, Sahraee Z, Mirahmadi M. The Patients' Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter pylori Eradication Regimens. J Clin Diagn Res. 2013;7:462-6
Abdi S, Abbasinazari M, Valizadegan G, Kamarei M, Panahi Y, Sarafzadeh F, et al. Does the Addition of Melatonin to Quadruple Therapy Increases the Eradication Rate of Helicobacter pylori? A Double-Blind Randomized Clinical Trial. J Clin Diagn Res. 2018;12:FC12 – FC14
Memariani Z, Sharifzadeh M, Bozorgi M, Hajimahmoodi M, Farzaei MH, Gholami M, Siavoshi F, Saniee P. Protective effect of essential oil of Pistacia atlantica Desf. on peptic ulcer: role of α-pinene. J Tradit Chin Med. 2017;37:57-63
Barberio B, Yiannakou Y, Houghton LA, Black CJ, Savarino EV, Ford AC. Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. Clin Gastroenterol Hepatol. 2022;20:e89-e101
- Abstract Viewed: 629 times
- PDF Downloaded: 231 times